Compliment Corporation logo

Compliment Corporation

Compliment Corporation is a start-up biotechnology company developing revolutionary therapeutics in oncology, a multi-billion-dollar market opportunity. Our mission is to improve cancer treatment by dramatically increasing the effectiveness of cancer drugs and by reducing the toxicities associated with standard chemotherapy treatment. The company’s technology targets immune signaling molecules and tight junction architecture proteins in order to remodel tumor cells allowing easy killing by monoclonal antibodies and chemotherapeutics. We are in the process of optimizing production of the small proteins that have these effects and are looking for funds to test the therapies in people.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://complimentcorp.com
Disease Focus
STOCK CODENon Listed
Address
Eastlake Avenue East, Suite 400, WA 98102
Seattle
United States
Email
Contact Number
+1 206-623-0331

Compliment Corporation is a start-up biotechnology company focused on improving cancer treatment by increasing the effectiveness of cancer drugs and by reducing the toxicities associated using its lead products Opus_ and AugmAb_.

Darrick Carter, a biophysicist co-founded Compliment corporation along with Andr_ Lieber a Professor of Medicine, and an expert in the biology of adenoviruses and cancer immunotherapy with the aim of effectively improve the potential treatment of cancer with the help of the lead products.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]

Compliments proprietary technology platform generates novel engineered proteins derived from the non-immunogenic portion of adenoviruses that increase the efficacy and decrease the toxicity of widely used cancer therapies, such as monoclonal antibodies and chemotherapy drugs.
(a)Its lead product Opus_ selectively opens intercellular junctions between tumor cells, increasing penetration of monoclonal antibodies and chemotherapy thereby increasing their efficacy and reducing toxicity.(b) AugmAb_-it counteracts complement-inhibitory protein CD46 that is up-regulated on tumor cells increasing efficacy of monoclonal antibodies.